Monographie - Tirofiban - Stabilis 4.0

Poslední aktualizace :
19/11/2024

Antikoagulans

Tirofiban

injekce

Stabilita roztoků

Stabilita směsí

Faktory ovlivňující stabilitu

Kompatibilita

Způsoby aplikace

Odkazy

pdf

Obchodní název

Obchodní název

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aggrastat	Austrálie, Belgie, Dánsko, Finsko, Írán, Irsko, Itálie, Kanada, Lucembursko, Malajsie, MaÔarsko, NÏmecko, Nizozemsko, Norsko, nový Zéland, Polsko, Portugalsko, Rakousko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Švýcarsko, Turecko, USA, Velká Británie
Agrastat	äpanÏlsko, Argentina, BrazÌlie, Chile, Egypt, Ekvádor, Francie, Kolumbie, Maroko, Mexiko, Peru, Venezuela
Thrombostat	Turecko
Tirofiban	äpanÏlsko, NÏmecko
Tiroprest	Turecko
Welban	äpanÏlsko
Xtraban	Indie

Odkazy

injekce

Odkazy : Tirofiban

	typ	uveřejnění
1071	noviny	Bergquist PA, Zimmermann J, Kenney RR, Han RYH, Hunke WA. Stability of tirofiban hydrochloride in three commonly used IV solutions and polyvinyl chloride administration sets. Am J Health-Syst Pharm 1999 ; 56: 1627-1629.
1420	noviny	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1508	noviny	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratoř	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1600	noviny	Garabito MJ, Jimenez L, Bautista J, Santos-Rubio MD, Perez Rodrigo I. Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days. Am J Health-Syst Pharm 2001 ; 58: 1850-1851.
1603	noviny	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611	noviny	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1713	noviny	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
2004	noviny	Patel K, Hursting MJ. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1381-1384.
3823	noviny	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.

Mentions Légales